Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Mimeault, Murielle ^a   Johansson, Sonny L ^a   Batra, Surinder K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR; GDF15 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RISK; CANCER STEM CELL; CANCER TISSUE; CELL FRACTIONATION; CELL RENEWAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYTOLOGY; DISEASE COURSE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; NICK END LABELING; PROSTATE TUMOR;

ANTIGENS, CD; CELL PROLIFERATION; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOPLASTIC STEM CELLS; NF-KAPPA B; PEPTIDES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84857601265     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031919     Document Type: Article

References (80)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
4. Mimeault M, Batra SK, (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22.
5. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G, (2008) The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15: 3866-3871.
6. Freedland SJ, (2010) Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117: 1123-1135.
7. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'amico AV, et al. (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60: 70-98.
8. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490.
9. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269.
10. Mimeault M, Mehta PP, Hauke R, Batra SK, (2008) Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev 29: 234-252.
11. Feldman BJ, Feldman D, (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
12. Ellem SJ, Wang H, Poutanen M, Risbridger GP, (2009) Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol 175: 1187-1199.
13. Mimeault M, Batra SK, (2011) Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med 17: 949-964.
14. Mimeault M, Batra SK, (2011) Animal models of prostate carcinogenesis underlining the critical implication of prostatic stem progenitor cells. Biochim Biophys Acta 1816: 25-37.
15. Merseburger AS, Hennenlotter J, Simon P, Muller CC, Kuhs U, et al. (2006) Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16: 79-83.
16. Torring N, Gnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE, (2003) ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 56: 142-149.
17. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, et al. (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13: 197-210.
18. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, et al. (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444.
19. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, et al. (2006) Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations. J Urol 176: 532-537.
20. Shah RB, Ghosh D, Elder JT, (2006) Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66: 1437-1444.
21. Ayala G, Thompson T, Yang G, Frolov A, Li R, et al. (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10: 6572-6578.
22. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, et al. (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10: 5501-5507.
23. Shukla S, MacLennan GT, Hartman DJ, Fu P, Resnick MI, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424-1432.
24. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F, (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65: 130-140.
25. Ayala GE, Dai H, Ittmann M, Li R, Powell M, et al. (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64: 6082-6090.
26. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, et al. (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10: 2466-2472.
27. Chen SJ, Karan D, Johansson SL, Lin FF, Zeckser J, et al. (2007) Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 67: 557-571.
28. Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, et al. (2009) Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 69: 652-661.
29. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, et al. (2010) Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 9: 1293-1302.
30. Huang CY, Beer TM, Higano CS, True LD, Vessella R, et al. (2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 13: 5825-5833.
31. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, et al. (2009) Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 69: 7696-7703.
32. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, et al. (2011) Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 11: 31.
33. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, et al. (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628.
34. Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, Lin MF, et al. (2006) Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 118: 1022-1031.
35. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, et al. (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579-6584.
36. Mimeault M, Johansson SL, Venkatraman G, Moore E, Henichart JP, et al. (2007) Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 6: 967-978.
37. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, et al. (2010) Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 16: 1245-1255.
38. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, et al. (2007) Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120: 160-169.
39. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, et al. (2007) Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 16: 532-537.
40. Maitland NJ, Bryce SD, Stower MJ, Collins AT, (2006) Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc 5: 155-179.
41. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
42. Rowehl RA, Crawford H, Dufour A, Ju J, Botchkina GI, (2008) Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 5: 301-310.
43. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, et al. (2009) In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 69: 1683-1693.
44. Wei C, Guomin W, Yujun L, Ruizhe Q, (2007) Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line? Cancer Biol Ther 6: 763-768.
45. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG, (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796-6805.
46. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
47. Li T, Su Y, Mei Y, Leng Q, Leng B, et al. (2009) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 30: 234-244.
48. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, et al. (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70: 5163-5173.
49. Gu G, Yuan J, Wills M, Kasper S, (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815.
50. Liu T, Xu F, Du X, Lai D, Liu T, et al. (2010) Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 340: 265-273.
51. Fan X, Liu S, Su F, Pan Q, Lin T, (2011) Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol Oncol.
52. Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK, (2010) Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and non-side population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 9: 617-630.
53. Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, et al. (2011) Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 317: 262-275.
54. Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL, (2010) Genomic profiling of tumor initiating prostatospheres. BMC Genomics 11: 324.
55. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26: 433-446.
56. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 5: e12445.
57. Bae KM, Su Z, Frye C, McClellan S, Allan RW, et al. (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 183: 2045-2053.
58. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, et al. (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9: R83.
59. Bisson I, Prowse DM, (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19: 683-697.
60. Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S, et al. (2010) MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett 295: 69-84.
61. Mimeault M, Batra S, (2009) Characterization of non-malignant and malignant prostatic stem/progenitor cells by Hoecsht side population method. Methods Mol Biol 568: 139-149.
62. Lieberman R, (2004) Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 11: 501-506.
63. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, et al. (2009) A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 9: 14.
64. Lakhey M, Ghimire R, Shrestha R, Bhatta AD, (2010) Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. Kathmandu Univ Med J (KUMJ) 8: 158-163.
65. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G, (2010) Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR 93: 62-70.
66. Epstein JI, (2004) Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 17: 307-315.
67. Graff JN, Beer TM, (2011) Toward predictors of survival in castration-resistant prostate cancer. Cancer 117: 3882-3884.
68. Dalfior D, Delahunt B, Brunelli M, Parisi A, Ficarra V, et al. (2010) Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy. Pathology 42: 1-5.
69. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, et al. (2010) A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71: 700-710.
70. Donovan MJ, Khan FM, Bayer-Zubek V, Powell D, Costa J, et al. (2011) A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer. BJU Int 109: 207-213.
71. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, et al. (2011) A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med 9: 43.
72. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, et al. (2009) Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69: 8555-8562.
73. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, et al. (2007) Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 67: 9089-9096.
74. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273.
75. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, et al. (2006) Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12: 5578-5586.
76. Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, et al. (2006) Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 66: 1498-1511.
77. Brown DA, Stephan C, Ward RL, Law M, Hunter M, et al. (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 12: 89-96.
78. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, et al. (2009) Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 15: 6658-6664.
79. Mimeault M, Mehta PP, Hauke R, Moore E, Henichart JP, et al. (2007) Improvement of cytotoxic effects of mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Growth Factors 25: 400-416.
80. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, et al. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 69: 827-837.